Is the business good?
How good a business is VRDN?
Viridian Therapeutics, Inc. keeps −570% of every revenue dollar as operating profit, against −72% for the median Biotechnology name.
−570%
Operating margin · Biotechnology median −72% · 12 months to Q2 2026
- R&D as % of revenue
- 456%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −10512% |
| FY2021 | −2691% |
| FY2022 | −7579% |
| FY2023 | −81035% |
| FY2024 | −99018% |
| FY2025 | −513% |
Details›
- Operating margin12 months to Q2 2026
- −570%
- Net margin12 months to Q2 2026
- −544%
- Free cash flow margin
- −471%
- R&D as % of revenue
- 456%
- Revenue, trailing twelve months
- $71M
- Free cash flow, trailing twelve months
- −$335M
- Net income, trailing twelve months
- −$387M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.